295 related articles for article (PubMed ID: 15535426)
1. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
[TBL] [Abstract][Full Text] [Related]
2. Orphan G protein-coupled receptors and obesity.
Xu YL; Jackson VR; Civelli O
Eur J Pharmacol; 2004 Oct; 500(1-3):243-53. PubMed ID: 15464037
[TBL] [Abstract][Full Text] [Related]
3. Alternative drug discovery approaches for orphan GPCRs.
Levoye A; Jockers R
Drug Discov Today; 2008 Jan; 13(1-2):52-8. PubMed ID: 18190864
[TBL] [Abstract][Full Text] [Related]
4. G protein-coupled receptors as targets for anti-diabetic therapeutics.
Oh DY; Olefsky JM
Nat Rev Drug Discov; 2016 Mar; 15(3):161-72. PubMed ID: 26822831
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological targeting of adipocytes/fat metabolism for treatment of obesity and diabetes.
Pilch PF; Bergenhem N
Mol Pharmacol; 2006 Sep; 70(3):779-85. PubMed ID: 16760360
[TBL] [Abstract][Full Text] [Related]
6. GPR43: an emerging target for the potential treatment of type 2 diabetes, obesity and insulin resistance.
Tiwari A
Curr Opin Investig Drugs; 2010 Apr; 11(4):385-93. PubMed ID: 20336586
[TBL] [Abstract][Full Text] [Related]
7. Endocrine receptors as targets for new drugs.
Altman J
Neuroendocrinology; 2006; 83(5-6):282-8. PubMed ID: 16926529
[TBL] [Abstract][Full Text] [Related]
8. Deorphanisation of G protein-coupled receptors: A tool to provide new insights in nervous system pathophysiology and new targets for psycho-active drugs.
Lecca D; Abbracchio MP
Neurochem Int; 2008 Feb; 52(3):339-51. PubMed ID: 17884255
[TBL] [Abstract][Full Text] [Related]
9. Interdependence of hepatic lipid and glucose metabolism: novel pharmacological targets for diabetes.
Lind P
Curr Opin Investig Drugs; 2004 Apr; 5(4):395-401. PubMed ID: 15134280
[TBL] [Abstract][Full Text] [Related]
10. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease.
Hutchinson DS; Summers RJ; Bengtsson T
Pharmacol Ther; 2008 Sep; 119(3):291-310. PubMed ID: 18606183
[TBL] [Abstract][Full Text] [Related]
11. The future of G protein-coupled receptors as targets in drug discovery.
Lundstrom K
IDrugs; 2005 Nov; 8(11):909-13. PubMed ID: 16254784
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment.
André A; Gonthier MP
Int J Biochem Cell Biol; 2010 Nov; 42(11):1788-801. PubMed ID: 20541029
[TBL] [Abstract][Full Text] [Related]
13. How well do rapid-acting insulins work in obese individuals?
Barnett AH
Diabetes Obes Metab; 2006 Jul; 8(4):388-95. PubMed ID: 16776745
[TBL] [Abstract][Full Text] [Related]
14. [GPCRs heterodimerization: a new way towards the discovery of function for the orphan receptors?].
Levoye A; Jockers R
Med Sci (Paris); 2007; 23(8-9):746-50. PubMed ID: 17875294
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-DomÃnguez A; Comuzzie AG
Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
[TBL] [Abstract][Full Text] [Related]
16. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
17. Addressing the unmet medical need for safe and effective weight loss therapies.
Arbeeny CM
Obes Res; 2004 Aug; 12(8):1191-6. PubMed ID: 15340099
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia.
Bernard J
Curr Opin Investig Drugs; 2008 Oct; 9(10):1078-83. PubMed ID: 18821469
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
Correia ML; Haynes WG
Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
